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Objectives: L-Arginine may improve cardioplegic protection by increas-
ing nitric oxide production. However, L-arginine may also be detrimen-
tal because it generates the free radical peroxynitrite. It would, there-
fore, be advantageous if the benefits of L-arginine could be achieved by
another means. Methods: Twenty neonatal piglets underwent 60 minutes
of ventilator hypoxia (inspired oxygen fraction 8%-10%) followed by 20
minutes of ischemia on cardiopulmonary bypass (stress) and were then
protected for 70 minutes with multiple doses of blood cardioplegic solu-
tion. In 5 piglets (group 1), the cardioplegic solution was not modified;
in 5 (group 2), low-dose L-arginine (4 mmol/L) was added; in 5 (group
3), prostaglandin E1 (alprostadil, 4 m g/L) was added; and in 5 (group 4),
the cardioplegic solution was passed through a leukodepleting filter.
Myocardial function was assessed by pressure volume loops and
expressed as percentage of control, and coronary vascular resistance
was measured with each cardioplegic infusion. Results: Unmodified
blood cardioplegic solution (group 1) was unable to protect the severely
stressed myocardium, resulting in depressed systolic function (39% ±
1%) and preload recruitable stroke work (40% ± 1%), increased dias-
tolic stiffness (239% ± 3%), and high conjugated diene production,
myeloperoxidase activity, and coronary vascular resistance. In contrast,
cardioplegic solutions modified with L-arginine, prostaglandin E1, or
leukodepletion, resuscitated the stressed myocardium, resulting in com-
plete return of systolic function (100% vs 101% vs 101%; P < .001 vs
group 1) and preload recruitable stroke work (100% vs 101% vs 101%;
P < .001 vs group 1), minimal increase in diastolic stiffness (160% vs
162% vs 160%; P < .001 vs group 1), and lowered conjugated diene pro-
duction, myeloperoxidase activity, and coronary vascular resistance
(P < .001 vs group 1 for each). Conclusions: (1) Unmodified blood cardio-
plegic solution is unable to protect the severely stressed myocardium. (2)
L-Arginine, prostaglandin E1, and leukocyte filtration all improve
myocardial protection equally and appear to work by limiting a white
blood cell–mediated injury. This reduces oxygen-derived free radical
formation, maintains vascular function, and restores functional recov-
ery. Since L-arginine may be detrimental, surgeons should consider
using prostaglandin E1 and/or a leukocyte filter instead.
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A t lower concentrations, L-arginine improves myo-cardial protection by increasing nitric oxide pro-
duction.1-5 However, at higher concentrations, nitric
oxide is detrimental because of overproduction of the
toxic oxygen radical peroxynitrite.2,5-8 It would there-
fore be advantageous if the beneficial effects of L-argi-
nine (nitric oxide) could be achieved by another
method since the optimum dose of L-arginine, as well
as whether nitric oxide production or inhibition is
desired, varies depending on several factors. White
blood cell (WBC) filters have been shown to reduce the
reperfusion injury, and because one of the actions of
nitric oxide is to prevent WBC adherence, leukodeplet-
ing the cardioplegic solution should have a similar
effect.9-11 Nitric oxide, however, also promotes vasodi-
lation, as well as decreasing platelet adherence; thus a
WBC filter does not completely mimic its actions.
Prostaglandins are secreted by vascular endothelial
cells and may be one of the mediators by which nitric
oxide works.7,12-14 Prostaglandins promote vasorelax-
ation, as well as preventing WBC and platelet adher-
ence, and therefore more closely mimic the actions of
nitric oxide. By investigating cardioplegic solutions
with and without L-arginine, leukodepleted, and sup-
plemented with prostaglandin E1 (PGE1, alprostadil),
this study aims (1) to elucidate whether the primary
beneficial effect of nitric oxide is vasodilatation, pre-
vention of a WBC-mediated injury, or both, and (2) to
provide an alternative approach to L-arginine for
improving myocardial protection.
Materials and methods
Twenty neonatal (5-18 days old) piglets (3.5-5 kg) were
premedicated with ketamine (40 mg/kg) intramuscularly and
anesthetized with phenobarbital (30 mg/kg) intraperitoneally,
followed by 5 mg/kg intravenously each hour. The lungs were
ventilated via a tracheotomy with a volume ventilator (Servo
900B, Siemens/Elema, Solna, Sweden). All animals received
humane care in compliance with the “Principles of
Laboratory Animal Care,” formulated by the National Society
for Medical Research, and the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources, National Research Council, and published
by the National Academy Press, revised 1996. The experi-
mental preparation, including cannulation for bypass and
blood sample procurement, is comparable to that previously
described.15,16
Experimental protocols
Hypoxic-ischemic stress. Twenty piglets underwent a
hypoxic-ischemic stress as previously described by lowering
the fraction of inspired oxygen to 8% to 10% for 60 minutes
(ventilator hypoxia), followed by cardiopulmonary bypass at
an inspired oxygen fraction of 100% for 5 minutes (reoxy-
genation), and finally clamping the aorta for 20 minutes at
37°C (normothermic ischemia).5 Piglets then underwent 70
minutes of cardioplegic arrest according to the protocol
described below.
Administration of cardioplegic solution. Cardioplegic solu-
tions (CAPS Service, Research Medical Inc, Salt Lake City,
Utah) are shown in Tables I and II. After the 20-minute nor-
mothermic-ischemic insult (see above), piglets underwent 70
minutes of cardioplegic arrest. The protocol, previously
described, consisted of 5 minutes of warm (37°C) induction
(Table I) followed by 4 minutes of cold multidose cardiople-
gia (Table II), a 2-minute cold multidose infusion every 20
minutes, and a 4-minute warm (37°C) cardioplegic reper-
fusate (“hot shot”) before aortic unclamping.5 Cardioplegic
solution was always infused at a continuously measured aor-
tic root pressure of 40 to 50 mm Hg. All piglets were weaned
from cardiopulmonary bypass with no inotropic support 30
minutes after aortic unclamping. Final functional and bio-
chemical measurements were made 30 minutes after arterial
blood gas, Ca2+, and K+ levels were normalized.
Experimental groups. Piglets were divided into 4 groups
on the basis of the composition of the cardioplegic solution.
Unmodified blood cardioplegic solution (group 1). In 5
piglets, the blood cardioplegic solution was not enriched with
L-arginine or PGE1 or passed through a leukocyte filter.
L-Arginine (group 2). In 5 piglets, the cardioplegic solution
was enriched with L-arginine (4 mmol/L).
Prostaglandin (group 3). In 5 piglets, the cardioplegic solu-
tion was supplemented with PGE1 (alprostadil, 4 m g/L).
WBC filter (group 4). In the final 5 piglets, the cardioplegic
solution was passed through a Pall BC-1 leukocyte depleting
filter (Pall Corp, G1en Cove, NY) before administration.
Myocardial oxygen consumption. After cardioplegic
arrest, blood was obtained at 1-minute intervals from the car-
dioplegia line and coronary sinus over the 5 minutes of warm
cardioplegic induction, and myocardial oxygen consumption
was calculated as previously described.17 The cumulative 5-
minute myocardial oxygen consumption was determined by
the sum of the individual 1-minute values and expressed per
100 g of heart tissue.
Myocardial performance. Left ventricular (LV) pressure
and conductance catheter signals were amplified and digi-
tized to inscribe LV pressure volume loops, the end-systolic
and end-diastolic pressure volume relationship, and preload
recruitable stroke work, analyzed as previously de-
scribed.5,15-18 Measurements were made before hypoxia
(baseline) and 30 minutes after cardiopulmonary bypass was
discontinued. Functional measurements are expressed as
absolute values as well as percent recovery of baseline val-
ues, with each piglet acting as its own control. After final
hemodynamic measurements, all piglets were placed back on
bypass and hearts were arrested with cold (4°C) blood car-
dioplegic solution. Transmural LV biopsy specimens were
obtained, as previously described, for biochemical analysis
and myocardial water.5
Physiologic measurements. Coronary vascular resistance
(CVR) was determined during each cardioplegic infusion by
measuring coronary sinus pressure and cardioplegic flow
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once a constant infusion rate with an aortic root pressure
between 40 and 50 mm Hg was achieved. CVR was calculated
as previously described and expressed as dynes · sec · cm–5.15,16
Biochemical analysis
Production of conjugated dienes. Blood samples were
obtained from the cardioplegia line and coronary sinus 1 and
5 minutes after the start of warm cardioplegia induction, and
myocardial conjugated dienes were assessed as previously
described.5 Production of conjugated diene was expressed per
100 gm heart tissue by weighing the left ventricle at the con-
clusion of the experiment.
Adenosine pool and myeloperoxidase activity. The adeno-
sine pool and quantitative myeloperoxidase activity were
determined as described previously.5,11,15 Adenosine triphos-
phate (ATP) levels are expressed as micrograms per gram of
dry tissue and myeloperoxidase activity as the change in opti-
cal density per minute per milligram of tissue protein
(D OD/min/mg protein).
Antioxidant reserve capacity. Myocardial antioxidant
reserve capacity was determined as described previously by
exposing the tissue to a 4 mmol/L concentration of t-butylhy-
droperoxide and measuring the production of malondialde-
hyde.5,19 Antioxidant reserve capacity is expressed as malon-
dialdehyde production in nanomoles per gram protein of
heart tissue. The greater the production of malondialdehyde
to the oxidant stress (t-butylhydroperoxide), the lower the
levels of endogenous tissue antioxidants (lower antioxidant
reserve capacity), indicating prior exposure of the myocardial
tissue to oxygen-derived free radicals during reperfusion.
Myocardial water. The percent myocardial water was cal-
culated as previously described by placing ventricular sam-
ples in preweighed vials and drying to a constant weight at a
temperature of 85°C.5
Statistics. Data were analyzed with JMP V2.0 software
(SAS Institute, Inc, Cary, NC) on a Macintosh IIVX comput-
er (Apple Inc, Cupertino, Calif). The paired Student t test and
1-way analysis of variance were used for comparison of vari-
ables among experimental groups. If the analysis of variance
revealed a significant interaction, pair-wise tests of individual
group means were compared by means of multiple compar-
isons (Tukey’s test) using a level of significance of P < .05, P
< .01, and P < .001. Group data are expressed as mean ± stan-
dard error of the mean.
Results
There was no significant difference (P > .2) between
groups for baseline (prehypoxic) values of LV contrac-
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Table I. Warm blood cardioplegic solution
Volume added Concentration 
Cardioplegia additive (mL) Component modified delivered*
KCl (2 mEq/mL) 10 K+ 8-10 mEq/L
THAM (0.3 mol/L) 225 pH pH 7.5-7.7
CPD 225 Ca2+ 0.2-0.3 mmol/L
Aspartate/glutamate 250 Substrate 13 mmol/L each
D50W 40 Glucose <400 mg/dL
D5W 200 Osmolarity 380-400 mOsm
L-Arginine† 50 Nitric oxide 4 mmol/L (group 2)
PGE1‡ (500 m g/mL) .04 Vasodilator WBC inhibitor 4 m g/L
THAM, Tromethamine; CPD, citrate-phosphate-dextrose; D50W, 50% dextrose in water; D5W, 5% dextrose in water; PGE1, prostaglandin E1.
*When mixed in a 4:1 ratio with blood.
†In group 2 piglets, 20 mmol of L-arginine was mixed in 50 mL of D5W before being added to the cardioplegic solution.
‡Added in group 3 piglets only.
Table II. Cold multidose blood cardioplegic solution
Volume added Concentration 
Cardioplegia additive (mL) Component modified delivered*
KCl (2 mEq/mL) 10 K+ 8-10 mEq/L
THAM (0.3 mol/L) 200 pH pH 7.6-7.8
CPD 50 Ca2+ 0.5-0.6 mmol/L
D5W 1⁄4 NS 550 Osmolarity 340-360 mOsm
L-Arginine† 50 Nitric oxide 4 mmol/L 
PGE1‡ (500 m g/mL) .035 Vasodilator WBC inhibitor 4 m g/L
THAM, Tromethamine; CPD, citrate-phosphate-dextrose; D5W, 5% dextrose in water; NS, normal saline solution; PGE1, prostaglandin E1.
*When mixed in a 4:1 ratio with blood.
†In group 2 piglets, 17 mmol of L-arginine was mixed in 50 mL of D5W before being added to the cardioplegic solution.
‡Added in group 3 piglets only.
tility, diastolic compliance, or preload recruitable
stroke work. All piglets tolerated 60 minutes of hypox-
ia with stable hemodynamics.
Hemodynamic and physiologic measurements.
Results are depicted in Table III and Figs 1 to 4. There
was no significant change or difference (P > .2) in the
X-axis intercept for end-systolic elastance or preload
recruitable stoke work between prebypass (baseline)
and postbypass values in any experimental group.
Therefore, the change in the slope of end-systolic elas-
tance and preload recruitable stroke work can be inter-
preted to express variability in the contractile state of
the myocardium compared with baseline values. This
allows the change in slope to be expressed as a per-
centage of baseline with each piglet acting as its own
control. Unmodified blood cardioplegic solution (group
1) was unable to resuscitate the severely stressed
(hypoxic-ischemic) myocardium, resulting in de-
creased postbypass systolic contractility, markedly
increased diastolic stiffness, and reduced preload re-
cruitable stroke work. In contrast, cardioplegic solution
supplemented with L-arginine (group 2), PGE1 (group
3), or passed through a WBC filter (group 4) resusci-
tated and protected the severely stressed myocardium,
resulting in complete return of systolic function and
preloaded recruitable stroke work, and minimally
increased diastolic stiffness. These values (groups 2-4)
were not statistically different (P > .2) from each other,
indicating similar beneficial effects for all 3 interven-
tions with regard to myocardial functional recovery.
The Pall BC-1 leukodepleting filter was extremely effi-
cient at lowering the concentrations of WBCs (13.2 ±
0.4 prefilter vs 0.3 ± 0.1 postfilter) and neutrophils (7.5
± 0.3 prefilter vs 0.2 ± 0.1 postfilter), but only mildly
reduced the platelet count (234 ± 12 prefilter vs 139 ±
10 postfilter).
Tissue studies. Results are summarized in Table IV.
Unmodified blood cardioplegic solution caused a sig-
nificant oxygen-derived free radical–mediated reperfu-
sion injury documented by the high production of con-
jugated dienes during cardioplegic induction
(reperfusion) and the decreased tissue antioxidant
reserve capacity (high malondialdehyde production).
The myeloperoxidase activity was increased, suggest-
ing that this injury may be mediated by WBCs, and the
ATP/ADP ratio, which is an indirect measurement of
mitochondrial function, was decreased. In contrast, the
production of oxygen-derived free radicals was equally
prevented (lower conjugated dienes and higher antiox-
idant reserve capacity) by supplementing the cardio-
plegic solution with L-arginine or PGE1 or by passing it
through a WBC filter. The myeloperoxidase activity
was also equally decreased in these 3 groups. Reducing
oxygen-derived free radical production prevented mito-
chondrial damage (preservation of the ATP/ADP ratio),
allowing the mitochondria to replenish ATP to normal
levels and resulting in a significantly higher myocardial
oxygen consumption during warm cardioplegic induc-
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Table III. LV function
End-systolic elastance Diastolic compliance Preload recruitable stroke work
c % b % Control c %
Group Intercept Slope* Recovery Coefficient stiffness Intercept Slope† Recovery
Unmodified blood 
cardioplegia (group 1)
Baseline 6.5 ± 0.1 34 ± 2 – 0.04 ± 0.01 – 10.6 ± 0.3 66 ± 3 –
Postbypass 6.7 ± 0.2 14 ± 2 41% ± 2%‡ 0.1 ± 0.02 267% ± 7%‡ 10.5 ± 0.1 26 ± 3 39% ± 2%‡
L-Arginine (group 2)
Baseline 6.3 ± 0.2 36 ± 1 – 0.05 ± 0.02 – 10.8 ± 0.1 69 ± 3 –
Postbypass 6.5 ± 0.1 36 ± 2 100% ± 2% 0.08 ± 0.01 160% ± 4% 10.7 ± 0.3 69 ± 2 100% ± 2%
PGE1 (group 3)
Baseline 6.6 ± 0.2 38 ± 2 – 0.05 ± 0.01 – 10.3 ± 0.3 65 ± 2 –
Postbypass 6.8 ± 0.2 39 ± 1 101% ± 1% 0.08 ± 0.02 161% ± 4% 10.5 ± 0.1 66 ± 2 101% ± 1%
WBC filter (group 3)
Baseline 6.4 ± 0.1 37 ± 1 – 0.05 ± 0.02 – 10.3 ± 0.1 65 ± 2 –
Postbypass 6.7 ± 0.2 38 ± 1 101% ± 2% 0.08 ± 0.01 162% ± 4% 10.5 ± 0.3 65 ± 1 101% ± 2%
F = 558 F = 250 F = 575
P < .001 P < .001 P < .001
c Intercepts expressed in mL.
*End-systolic elastance slope expressed in mm Hg/mL.
†Preload recruitable stroke work slope expressed as [∫(mm Hg · mL)/mL].
‡P < .001 vs groups 2, 3, and 4.
tion. Myocardial water, which is an indirect measure-
ment of cellular injury, was also lower and equivalent
in these groups (groups 2-4).
Discussion
L-Arginine improves myocardial protection through
its production of nitric oxide, which prevents WBC and
platelet adherence and induces vasorelaxation.1-4
However, L-arginine also produces the toxic oxygen-
derived free radical peroxynitrite and thus under certain
conditions it can be detrimental.5,6,20 Because it may be
difficult to determine under what conditions and at
what dose L-arginine may be harmful, an alternative
approach that achieves the same beneficial effects
would be advantageous. Prostaglandins are released by
endothelial cells and, like nitric oxide, prevent WBC
adherence and vasodilate coronary vessels.7,12-14,21
Whereas L-arginine needs to be converted to nitric
oxide by the intact endothelial cell, prostaglandins act
directly. Prostaglandins could therefore be superior in
the presence of damaged endothelium. PGE1 does not
produce oxygen radicals at higher doses, and this study
used a concentration of PGE1 that results in a low sys-
temic dose (0.03-0.04 m g · kg–1 · min–1). Systemic
doses up to 5 to 10 times this dose are routinely used
clinically without problems.21 A WBC filter does not
act directly on the vascular endothelium or cause
vasodilatation. It was therefore used in 1 group of
piglets to allow quantification of the contribution of
WBCs in mediating the reperfusion injury independent
of other factors (ie, vasodilation).
This study used both an ischemic and hypoxic stress
because each increases WBC adherence. This protocol
thus allowed the methods of protection to be tested in
vulnerable hearts. Furthermore, compared with hypox-
ia alone, the combination of hypoxia and ischemia may
more closely resemble the condition of the cyanotic
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Fig 1. Postbypass LV contractile function (hypoxic-ischemic
hearts). Recovery of LV systolic function as measured by end-
systolic elastance (EES) and expressed as percentage of control
(baseline). Note: Exposing the heart to hypoxia and ischemia
produces such a severe stress that aspartate-glutamate blood
cardioplegic solution is unable to fully resuscitate the heart. In
contrast, cardioplegic solution enriched with L-arginine, PGE1,
or passed through a WBC filter is able to fully resuscitate the
hypoxic myocardium, resulting in complete return of systolic
function. *P < 0.001 (mean ± standard error).
Fig 2. Postbypass LV diastolic compliance as measured by
the end-diastolic pressure volume relationship and expressed
as percentage of stiffness compared to control (baseline).
Note: There is a marked increase in diastolic stiffness in
hearts given blood cardioplegic solution alone. Conversely,
enriching the cardioplegic solution with L-arginine, PGE1, or
pumping it through a WBC filter allowed for cellular repair
of the hypoxic ischemia injury, improving diastolic compli-
ance. *P < 0.001 (mean ± standard error).
Fig 3. Postbypass overall myocardial function (hypoxic-
ischemic hearts). Recovery of overall myocardial function as
measured by preload recruitable stroke work (PRSW) and
expressed as a percentage of control (baseline). *P < 0.001
(mean ± standard error).
child.5,15,16,18,22-24 After a hypoxic-ischemic stress,
hearts protected with unmodified blood cardioplegic
solution sustained a significant oxygen-derived free
radical–mediated reperfusion injury resulting in vascu-
lar dysfunction (elevated CVR), mitochondrial dam-
age, and depressed myocardial function. In contrast,
oxygen-derived free radical production was equally
reduced if the cardioplegic solution was enriched with
L-arginine or PGE1 or was passed through a WBC fil-
ter. By avoiding the reperfusion injury, mitochondrial
function was preserved (ATP/ADP ratio), which
allowed energy levels to be replenished, resulting in
increased oxygen uptake during cardioplegic induc-
tion, as well as complete functional recovery. Com-
pared with L-arginine and PGE1, use of leukocyte fil-
tration resulted in similar levels of oxygen-derived free
radical production, myeloperoxidase activity, and
metabolic and functional recovery. This implies that
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Fig 4. Coronary vascular resistance (CVR) measured during cardioplegic infusions once the flow and cardioplegic
pressures were stable. Note: Because a WBC filter does not cause vasodilation, the lower CVR in groups 2 to 4
must be due to preservation of vascular function and not vasodilation. This also implies that L-arginine and PGE1
prevent vascular damage primarily by inhibition of a WBC-mediated injury. *P < 0.001 (mean ± standard error).
Table IV. Myocardial oxygen consumption and biochemical results
CD production*
(OD/mL/100 gm/min)MVO2* ARC† ATP Myocardial MPO 
(mL/100 gm/ (MDA nmol/ (m g/g ATP/ADP water (D OD/min/
Group 5 min) 1 min 5 min g protein) dry wt) ratio (%) mg protein)
Unmodified blood 6.7 ± 0.3‡ 72 ± 2‡ 74 ± 2‡ 1216 ± 26‡ 10.8 ± 0.6‡ 2.0 ± 0.3‡ 80.7 ± 0.2‡ 1.6 ± 0.1‡
cardioplegia (group 1)
L-Arginine (group 2) 10.2 ± 0.2 20 ± 2 21 ± 2 858 ± 28 16.1 ± 0.4 3.8 ± 0.3 79.7 ± 0.3 0.9 ± 0.1
PGE1 (group 3) 10.3 ± 0.1 21 ± 1 23 ± 2 854 ± 19 16.2 ± 0.3 3.6 ± 0.3 79.7 ± 0.2 0.8 ± 0.1
WBC filter (group 4) 10.4 ± 0.2 21 ± 1 23 ± 2 878 ± 21 16.3 ± 0.3 3.7 ± 0.4 79.6 ± 0.3 0.9 ± 0.1
F = 144 F = 518 F = 537 F = 110 F = 75.8 F = 16.6 F = 10.3 F = 15.6
P < .001 P < .001 P < .001 P < .001 P < .001 P < .001 P < .001 P < .001
MVO2, Myocardial oxygen consumption; CD, conjugated diene; OD, optical density; ARC, antioxidant reserve capacity; MDA, malondialdehyde; ATP, adenosine
triphosphate; ADP, adenosine diphosphate; MPO, myeloperoxidase.
*During cardioplegia induction (reperfusion).
†MDA production at 4 mmol/L t-butylhydroperoxide.
‡P < .001 versus groups 2, 3, and 4.
WBCs are responsible for the generation of the major-
ity of oxygen-derived free radicals during reperfusion
and that most of the beneficial effects of L-arginine and
prostaglandins are due to inhibition of WBC adher-
ence. We cannot prove, however, that all these modali-
ties work via an identical pathway, because we did not
specifically examine the mechanism of action with
each intervention. It is possible that L-arginine and
PGE1 limit the reperfusion injury via a non-WBC-
dependent mechanism or by a combination of effects,
since these agents also prevent platelet adherence and
induce vasodilatation. However, because one of the
primary effects of L-arginine (nitric oxide) and PGE1 is
to prevent adherence of activated WBCs, this mecha-
nism is probably responsible for a substantial portion
of their beneficial effects.
CVR was measured with each cardioplegic infusion
to determine whether any of the beneficial effects of L-
arginine or PGE1 were due to their ability to promote
vasodilatation.1-3,7,12,21,25 After an ischemic stress, the
coronary vasculature should be vasodilated. The higher
CVR with unmodified blood cardioplegic solution
(group 1) therefore implies vascular dysfunction result-
ing from endothelial cell injury. Conversely, the lower
CVR with L-arginine, prostaglandins, or WBC filtra-
tion implies avoidance of this injury with preservation
of vascular function. Because a WBC filter does not
cause vasodilatation, the similar CVR in these 3 groups
suggests that L-arginine and prostaglandins are acting
primarily to preserve vascular function through inhibi-
tion of WBCs, and not as vasodilators. This hypothesis
remains speculative because specific tests of vascular
endothelial cell function were not performed after
bypass. However, elevated CVR most likely indicates
vascular damage since it correlates with increased pro-
duction of oxygen-derived free radicals, mitochondrial
damage, and poor functional recovery.
We cannot determine whether combining a WBC fil-
ter with a pharmacologic agent (L-arginine and
prostaglandins) would further improve results, because
hearts receiving L-arginine, PGE1, or leukodepletion
recovered completely. However, because of differences
between these modalities, it is possible that they should
be used together. For instance, L-arginine is not as
effective when given cold, whereas WBC filters are rel-
atively unaffected by temperature. The optimal dosages
of L-arginine and prostaglandins are unknown in
human beings under various pathologic conditions;
therefore, if a low dose is used for safety, these agents
may not be as effective as they were in this study. Some
WBCs escape filtration, and leukocyte filters become
less efficient with greater volumes or higher flow rates.
A chemical (pharmacologic) blocker may help prevent
adhesion of these unfiltered leukocytes. L-Arginine and
prostaglandins also promote vasodilation, as well as
limiting platelet adherence.1,3,7,13,14,21,25 Increased vas-
cular resistance may limit cardioplegic distribution,
and platelet deposition results in capillary plugging
with release of potent vasocontrictors. In contrast, the
Pall BC-1 leukocyte-depleting filter only slightly
reduces platelet counts. The aforementioned factors
probably explain why Hiramatsu and associates2
demonstrated improvement when WBC filtration and
L-arginine were combined. Using a pharmaceutical
agent along with a WBC filter may therefore improve
myocardial protection in cyanotic children. However,
because of potential hazards with L-arginine, we would
recommend using prostaglandins, especially since they
have a similar effect.
In conclusion, L-arginine, PGE1, and leukocyte filtra-
tion all substantially and equally improve myocardial
protection by limiting a WBC-mediated injury, which
reduces oxygen-derived free radical production and
helps to restore endothelial, metabolic, and functional
recovery. Because pediatric patients are more sensitive
to surgical ischemia, as well as being prone to postby-
pass myocardial dysfunction, surgeons should consider
incorporating these modalities into their protective
strategies.
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Discussion
Dr Bradley Hofer (Seattle, Wash). Dr Allen, you and your
coauthors are to be congratulated on a well-designed study in
a model of neonatal, hypoxic, ischemic reperfusion injury. I
presume this model is meant to simulate cyanotic infants who
are then subjected to ischemic reperfusion with subsequent
hyperoxic cardiopulmonary bypass.
You used a model of combined subacute hypoxia followed
by ischemic stress in piglets. Do you believe these results are
applicable to adult mature myocardium and endothelium?
Dr Allen. To make the heart more sensitive to differences
in myocardial protection, we subjected piglets to an ischemic
and hypoxic stress. We used the combination of ischemia and
hypoxia because cyanotic infants often have depressed
myocardial ATP levels owing to episodes of ischemia that
occur during times of stress. Although our model might not
completely simulate the condition of the cyanotic infant, it
allows us to test different cardioplegia strategies in vulnera-
ble hearts. This is no different from simulating an ischemic
stress in adult studies by crossclamping the aorta. This may
not exactly simulate chronic angina, but it subjects the adult
heart to a clinically relevant stress. Investigating stressed
hearts is extremely important in both adult and pediatric stud-
ies, because they are the most difficult to protect. It is my
belief that the principles of this study are applicable to both
pediatric and adult patients. However, without a definitive
investigation, I cannot be certain. 
Dr Hofer. I was impressed that the effects on both the CVR
and myocardial oxygen consumption are immediate; 1
minute after your induction dose you see an amelioration of
these in all 3 groups. This is understandable in the WBC fil-
ter groups, since they theoretically have been treated the
entire course, before their induction therapy. However, how
can you explain this happening so rapidly in the PGE1 and the
nitric oxide groups? Does this imply that a very small dose at
the beginning of induction is sufficient, as opposed to a
longer infusion?
Dr Allen. The initial reintroduction of blood caused a
reperfusion injury in the unmodified group, resulting in an
increase in both oxygen-derived free radical production and
CVR. Conversely, this injury was avoided (low oxygen radi-
cal formation) if the cardioplegic solution was enriched with
PGE1, L-arginine, or leukodepleted, improving functional
recovery. Because oxygen-derived free radical formation and
CVR are decreased during cardioplegic induction with L-
arginine, PGE1, and leukodepletion, it is possible these agents
are not required after the initial period of reperfusion, or dur-
ing subsequent cardioplegic infusions. However, previous
studies suggest they need to be delivered for several minutes
to obtain maximal benefit. Furthermore, because these
modalities help prevent the reperfusion injury, and hearts are
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ischemic between cardioplegic infusions, they are probably
beneficial during each cardioplegic infusion. None of the
groups were pretreated. A WBC filter was used only to filter
leukocytes in the cardioplegic solution. Therefore, the only
difference between groups was the cardioplegic solution. The
PGE1 concentration was relatively low and equivalent to a
systemic dose of 0.2 to 0.4 µg · kg–1 · min–1, which is one fifth
of what is often used to keep a patent ductus open.
Dr Hofer. Since you are concerned that a higher dose of L-
arginine is injurious, would an experiment in which you apply
only one dose, as opposed to continuing through the whole
infusion, theoretically remove those injurious side effects?
Dr Allen. No, I do not believe so. In the previous study (see
page 655) we found a marked increase in oxygen radical for-
mation and CVR during cardioplegic induction if the con-
centration of L-arginine was increased. Therefore the detri-
mental effects of L-arginine seem to be dependent on the
concentration, not the total dose.
Dr Hofer. Would you expect the exact same results if you
were to give adenosine as a vasodilator or if you were to
block adhesion by another mechanism? 
Dr Allen. Yes, I believe the same results could be expect-
ed. There are dozens of prostaglandins as well as prostacyclin
and adenosine, all of which seem to have the similar actions
of limiting WBC and platelet adherence and inducing vasodi-
latation. We chose PGE1 because it is routinely used in
infants, it may be one of the mediators by which nitric oxide
works, and several studies have documented its effectiveness
in reducing reperfusion injury after ischemia. However, we
probably would have had similar results had we used adeno-
sine, prostacyclin, or a variety of other prostaglandins.
Dr Edward Verrier (Seattle, Wash). I am a bit concerned
about the conclusions. A number of other cells are involved
with hypoxic injuries, including endothelial cells and
platelets. Therefore, to say your observations are only medi-
ated by WBCs may be true but unrelated. One simple exper-
iment that could be done would be to add the different com-
ponents into the same solution and see whether the results
change. For instance, one could use either prostaglandin or
the WBC filter and see whether the factors are additive in
some fashion. The fact that you get the same level with each
intervention does not necessarily mean that they are mediat-
ed by exactly the same mechanism. 
Dr Allen. You are probably right. In addition to inhibiting
WBCs, prostaglandins block platelet adherence and induce
vasodilatation. These effects are also important in preventing
cellular injury after ischemia. Dr Mayer and associates
recently demonstrated that using L-arginine and WBC filters
together improved myocardial protection much more effec-
tively than using either modality separately. It may be that our
model was not severe enough to allow us to demonstrate the
added benefits of vasodilatation or decreased platelet adher-
ence. However, the present study does suggest that a major
beneficial effect of L-arginine and prostaglandin is due to
inhibition of WBC-mediated injury. Platelets and vascular
dysfunction definitely play a role in the pathogenesis of the
reperfusion injury, and modalities that also block these
adverse effects may be superior. We therefore believe that
WBC filters and chemical blockers, such as PGE1, should
probably be used together.
Dr Verrier. This type of hypoxic stress induces endothe-
lial cells, for instance, to up-regulate a huge number of
inflammatory mediators. They do not even get expressed
out until 4 hours. Thus the results that you report here are
very early-phase results and may be significantly different
from what would be seen at 6 hours (in terms of the return
of function).
Dr Allen. There may be an up-regulation of inflammatory
mediators that will increase the inflammatory response sever-
al hours later. Using L-arginine, PGE1, or leukodepletion,
however, prevented the initial production of free radicals dur-
ing reperfusion. By limiting the reperfusion injury, inflam-
matory up-regulation should at least be partially suppressed.
Furthermore, limiting the reperfusion injury may also allow
the cell to be less susceptible to any inflammatory mediators
several hours later.
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